Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-31
2010-10-19
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07816499
ABSTRACT:
The present invention features, inter alia, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2, which comprises a histone deacetylase catalytic domain at amino acids 635 to 953 of SEQ ID NO: 2, purified antibodies that selectively bind a biologically active fragment of the polypeptide of SEQ ID NO: 2, which fragment exhibits histone deacetylase activity, transcription repression activity, and the ability to deacetylate cellular substrates, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide encoded by a nucleotide sequence as set forth in SEQ ID NO: 1, purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 2 lacking a nuclear localization signal, and purified antibodies that selectively bind an isolated or recombinant histone deacetylase polypeptide having at least 95% amino acid sequence identity to SEQ ID NO: 2 and which exhibits histone deacetylase activity, transcription repression activity, and the ability to deacetylate cellular substrates.
REFERENCES:
patent: 5659016 (1997-08-01), Nakamura et al.
patent: 5763182 (1998-06-01), Nakamura et al.
patent: 6287843 (2001-09-01), Baldwin et al.
patent: 6673587 (2004-01-01), Evans et al.
patent: 7063973 (2006-06-01), Richon et al.
patent: 7244604 (2007-07-01), Richon et al.
patent: 2001/0010909 (2001-08-01), Cahoon et al.
patent: 2001/0012836 (2001-08-01), Hu et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: WO 97/35990 (1997-10-01), None
patent: WO 00/10583 (2000-03-01), None
patent: WO 01/18045 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/42437 (2001-06-01), None
patent: WO 02/36786 (2002-05-01), None
patent: WO 02/102323 (2002-12-01), None
Attwood, Science 290: 471-473, 2000.
Skolnick et al., Trends in Biotech. 18: 34-39, 2000.
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Li et al., PNAS 77: 3211-3214, 1980.
Buggy, et al. “Cloning and Characterization of a Novel Human Histone Deacetylase, HDAC8”,Biochem. J., 350:199-205, (2000).
Cress, et al. “Histone Deacetylases, Transcriptional Control, and Cancer”,Journal of Cellular Physiology, 184:1-16, (2000).
Dangond, et al. “Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-activated Immune Cells”,Biochem. Biophys. Res. Commun., 243(3):648-652, (1998).
Emiliani, et al. “Characterization of a Human RPD3 Ortholog, HDAC3”,Proc. Natl. Acad. Sci. USA, 95:2795-2800, (1998).
Fischle, et al. “A New Family of Human Histone Deacetylases Related toSaccharomyces cerevisiaeHDA1p”,The Journal of Biological Chemistry, 274(17):11713-11720, (1999).
Grozinger, et al. “Three Proteins Define a Class of Human Histone Deacetylases Related to Yeast HDa1p”,Proc. Natl. Acad. Sci. USA, 96:4868-4873, (1999).
Hegde, et al. (2000) “EST380989 MAGE Resequences, MAGJHomo sapienscDNA, mRNA Sequence”, Database EMBL Acc. No. AW968913, Abstract.
Hu, et al. “Cloning and Characterization of a Novel Human Class I Histone Deacetylase That Functions as a Transcriptional Repressor”,The Journal of Biological Chemistry, 275(20):15254-15264, (2000).
Macleod, et al. (2000) “Human Histone Deacetylase HDAC-5 Coding Sequence”, Database EMBL Acc. No. AAC89558, Abstract.
Macleod, et al. (2001) “Human Histone Deacetylase HDAC-5 Coding Sequence”, Database EMBL Acc. No. AAC89557, Abstract.
Marks, et al. “Historic Deacetylase Inhibitors as New Cancer Drugs”,Curr. Opin. Oncol., 13:477-483, (2001).
Marks, et al. “Histone Deacetylases and Cancer: Causes and Therapies”,Nat. Rev. Cancer, 1:194-202, (2001).
Miska, et al, “HDAC4 Deacetylase Associates With and Represses the MEF2 Transcription Factor”.The EMBO Journal, 18:5099-5107 (1999).
Nagase, et al. “Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro”,DNA Research, 5:277-286, (1998).
Richon, et al. “A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases”,Proc. Natl. Acad. Sci. USA, 95:3003-3007 (1998).
Sparrow, et al. “MEF-2 Function is Modified by a Novel Corepressor, MITR”,The EMBO Journal, 18:5085:5098, (1999).
Van den Wyngaert, et al. “Cloning and Characterization of Human Histone Deacetylase 8”,FEBS Lett., 478:77-83, (2000).
Wang, et al. “HDAC4, a Human Histone Deacetylase Related to Yeast HDA1, Is a Transcriptional Corepressor”,Molecular and Cellular Biology, 19:7816-7827, (1999).
Yang, et al. “A p300/CBP-associated Factor that Competes With the Adenoviral Oncoprotein E1A”,Nature, 382:319-324, (1996).
Yang et al. “Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family”,The Journal of Biological Chemistry, 272:28001-28007, (1997).
Zhang, et al. “The Transcriptional Corepressor MITR is a Signal-responsive Inhibitor of Myogenesis”,Proc. Natl. Acad. Sci. USA, 98:7354-7359, (2001).
Zhang, et al. “Association of COOH-terminal-binding Protein (CtBP) and MEF2-interacting Transcription Repressor (MITR) Contributes to Transcriptional Repression of the MEF2 Transcription Factor”,The Journal of Biological Chemistry, 276:35-39, (2001).
Zhang et al. “Mus Musculus MEF2-Interacting Transcription Repressor MITR (Mitr) mRNA, Comp. cds”, Database EMBLAcc. No. AF324492, (2001) Abstract.
Zhou, et al., “Identification of a Transcriptional Repressor Related to the Noncatalytic Domain of Histone Deacetylases 4 and 5”,Proc. Natl. Acad. Sci. USA, 97:1056-1061, (2000).
Zhou, et al. “Cloning and Characterization of a Histone Deacetylase, HDAC9”,PNAS, 98:10572-10577, (2001).
Zhou et al. “Mus Musculus Historic Deacetylase Related Protein mRNA”, Database EMBL Acc. No. AF235053, (2001) Abstract.
European Search Report dated Sep. 20, 2005.
Sequence Search Alignment Between Applicants' SEQ ID No. 1 of USP 7,244,604 and SEQ ID No. 1 of USP 6,673,587, Apr. 2006.
Marks Paul A.
Richon Victoria M.
Rifkind Richard A.
Zhou Xianbo
Elrifi Ivor R.
Gambel Phillip
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Sloan-Kettering Institute for Cancer Research
LandOfFree
Antibodies that selectively bind HDAC9 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that selectively bind HDAC9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that selectively bind HDAC9 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230420